Premium
[P2–011]: INCREASED PRO‐INFLAMMATORY SIGNALING AND EVIDENCE OF ALZHEIMER's DISEASE PATHOLOGY IN HEALTHY OLDER ADULTS AT RISK FOR AD
Author(s) -
Meyer PierreFrancois,
Poirier Judes,
RosaNeto Pedro,
Weitz Tara M.,
Town Terrence,
Labonte Anne,
Breitner John C.S.
Publication year - 2017
Publication title -
alzheimer's and dementia
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 6.713
H-Index - 118
eISSN - 1552-5279
pISSN - 1552-5260
DOI - 10.1016/j.jalz.2017.06.659
Subject(s) - medicine , biomarker , inflammation , placebo , disease , surrogate endpoint , cognitive impairment , oncology , pathology , gastroenterology , immunology , biology , biochemistry , alternative medicine
and anti-asthmatic drug Montelukast elevated hippocampal neurogenesis, reduced neuroinflammation, and improved learning and memory.Methods:AsMontelukast is known to have a low bioavailability, we were now aiming to optimize the pharmacology of Montelukast by improving its formulation.Results:In a Phase I study, we demonstrated that an oral film formulation of Montelukast (Montelukast VersaFilm) is safe and tolerable in healthy subjects, reduces the first-pass-effect and has a 52% higher bioavailability compared to the regular Montelukast tablet. Of importance for any CNSactive drugs, we detected Montelukast in the cerebrospinal fluid of the Montelukast VersaFilm treated healthy volunteers clearly indicating blood brain barrier penetrance. Of note, Montelukast, in contrast to many other CNS penetrating drugs, has an excellent safety and tolerability profile.We are at this stage preparing a Phase II trial to demonstrate efficacy of the Montelukast VersaFilm to improve cognitive function in AD. Conclusions:Montelukast VersaFilm might be a novel effective therapeutic entering the field of Alzheimer’s Disease to improve cognitive function.